Pharma M&A MasterClass
19 - 20 September, 2022
This Masterclass is intensive, and aimed at participants who wish to understand the various legal aspects of M&A in its different facets.
This online training takes participants through the whole legal process focusing on key legal and practical challenges for the constituent players, as well as provides sample legal documents to back up the presentation materials.
19 - 20 September, 2022, Virtual
Time Zone: UTC/GMT+1 /CET
This online training takes participants through the whole legal process focusing on key legal and practical challenges for the constituent players. As well as this online course provides sample legal documents to back up the presentation materials. This training will Addresses and clarifies the different types of warranties and due diligence in Life Sciences investment
#masterclass #glceurope #pharmaonlinetraining #globalleadingconferences #pharmaM&A
Who should attend?
• Company directors
• Private equity professionals
• Venture capitalists
• Investment bankers
• Corporate financiers
• M&A specialists
• Vendors and Purchasers
"High attention to detail in course content and very well delivered"
Product Development Manager
"Very good training led by two knowledgeable and open experts. Excellent insight given on many complex topics. Interactive and highly useful"
USP PD Team Manager
"Great course, impressed with the knowledge of the trainers and ability to answer wide variety of questions!"
Manager, Senior Investigator
MT Sword Laboratories (BMS)
Global Leadership Conferences began as an ambitious dream by three founders ten years ago. Today it’s an international series of interactive events, exploring the hottest topics in critical fields. Each year, thousands of professionals join us to challenge the status quo and learn innovative ways to create new solutions in Finance, Pharmaceutical, HR, Health & Safety, and Energy.know more >
Years of experience
Other events you may like
23 - 26 May, 2022
The focus of this two days pharma online masterclass will be on providing an update of ongoing activities regarding medicines’ risk and signal management.learn more >>